Skip to content

Clinical study of reperfusion combined with neuroprotection in the treatment of posterior circulation cerebral infarction

Clinical study of reperfusion combined with neuroprotection in the treatment of posterior circulation cerebral infarction

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044882
Enrollment
Unknown
Registered
2021-03-31
Start date
2021-03-31
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

posterior circulation cerebral infarction

Interventions

control group:reperfusion therapy
observation group:reperfusion combined with neuroprotective therapy

Sponsors

The First Affiliated Hospital of Suzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.The diagnosis was in accordance with the diagnostic criteria for acute cerebral infarction - posterior circulation cerebral infarction in the Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018; 2.The age was 18-80 years old; 3.The patient received intravenous thrombolysis (and / or mechanical thrombectomy) within 6 hours of stroke onset; 4.the patient or his family members signed the informed consent.

Exclusion criteria

Exclusion criteria: 1.Intracranial hemorrhage, previous history of intracranial hemorrhage; 2.History of severe head injury or stroke, intracranial tumor or giant intracranial aneurysm in recent 3 months; 3.Intracranial or intraspinal surgery in recent 3 months; 4.Active visceral hemorrhage; 5.Large surgical operation in recent 2 weeks or arterial puncture in recent 1 week; 6.Unknown onset time of symptoms; 7.Rapid improvement of symptoms or mild symptoms before thrombolytic therapy MS >= 3 before onset; 8.Severe stroke (NIHSS score > 24), large area infarction on CT or MRI; 9.Pregnant, pregnant planning or lactating women; 10.Patients with known allergy or contraindication to the drug components in this study; 11.Patients with severe liver insufficiency, renal insufficiency and cardiac insufficiency; 12.Life expectancy of patients with malignant tumor < 6 months; 13.Autoimmune diseases and blood system diseases; 14.Patients with acute cerebral infarction in anterior circulation area; patients participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Interleukin 2,4, 6, 10, 17A;tumor necrosis factor a;Interferon ?;Immunization package;

Countries

China

Contacts

Public ContactFang Qi

The First Affiliated Hospital of Suzhou University

fangqi_008@126.com+86 13606213892

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026